Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Alseres Pharmaceuticals -- Ignore unavailable to you. Want to Upgrade?

To: james who wrote (540)	1/3/1998 11:53:00 PM
From: GREATMOOD	Read Replies (1) \| Respond to of 975

To All: BLSI files an 8-K. freeedgar.com Boston Life Sciences, Inc. announced that its collaborating scientists have discovered in preclinical animal models and other laboratory tests that a heretofore unrecognized natural small molecule appeared to strongly stimulate axonal regeneration in nerve cells of the Central Nervous System (CNS). This molecule is the second apparent CNS axonal growth factor identified as part of the Company's CNS nerve regeneration discovery program. The Company believes that this new work demonstrates that neurons in the CNS may be actually capable of regenerating axonal connections between cells in response to certain endogenous growth factors in mammals. The Company's two nerve regeneration compounds are being studied in spinal cord injury models. If successful, the Company hopes to file an Investigational New Drug (IND) application for one or both compounds as soon as possible.